Key Highlights

  • 26% is how far Travere Therapeutics (NASDAQ:TVTX) trades below its USD 68.73 52-week high, at USD 50.95 on October 16, 2026 (own arithmetic on published market data). The 14-day RSI is 28.9, and the market capitalization is USD 4.80 billion.
  • September 21, 2026 is when Travere Therapeutics (NASDAQ:TVTX) announced that chief executive Eric Dube will step down, per the 8-K. Bradley Campbell, a former chief executive of Amicus Therapeutics, is named successor, with a December 1 start per published market data.
  • USD 141.1 million was second quarter Filspari net product sales, up 96% from USD 71.9 million, per the August 4 release. Total revenue was USD 169.6 million, the net loss USD 34.8 million, and cash and securities USD 489.2 million.
  • October 21 to 25, 2026 is the ASN Kidney Week window where Travere Therapeutics (NASDAQ:TVTX) plans nine Filspari presentations, five oral. Third quarter results are estimated for October 29, 2026, a date the company has not confirmed in filings reviewed.

Price Action and Catalyst Review

The market is asking whether a launch story can survive a leadership handover. Filspari, the company's kidney drug, gained a focal segmental glomerulosclerosis indication in April 2026, and revenue nearly doubled. The shares nonetheless closed October 15 at USD 52.79 and traded at USD 51.39 at the October 16 open, per published market data. No company-specific negative catalyst was identified in the filings and releases reviewed through October 16, 2026. The CEO announcement on September 21 and a notice of allowance in late September for method-of-use patents extending protection to 2037 are the main recent events; the one-week change is only 2.09%, so RSI reflects an earlier decline.

Filspari Economics and Balance Sheet

Think of Filspari as the engine and cash as the fuel gauge. Annualizing second quarter revenue of USD 169.6 million gives USD 678 million, a price to sales multiple of 7.1 (own arithmetic). Trailing twelve-month revenue of USD 591.33 million gives 8.1 times. Cash of USD 489.2 million equals 10.2% of market capitalization. With 94.17 million shares outstanding at June 30, the GAAP loss was USD 0.37 per basic share and the non-GAAP loss USD 0.10. Pegtibatinase Phase 3 topline data are not expected until the second half of 2027.

Valuation, Support and Risks

The 52-week range is USD 22.59 to USD 68.73. Consensus is Strong Buy from 15 analysts with a USD 75.21 average target, 47.6% above USD 50.95 (own arithmetic). Guggenheim raised its target to USD 89 from USD 75 in late September. Risks are concentration in one drug, risk evaluation and mitigation requirements, payer pressure, competition in rare kidney disease and execution under a new chief executive. Inducement equity grants announced October 12 add modest share supply. RSI below 30 describes speed, not direction.

Where Things Stand

Travere Therapeutics (NASDAQ:TVTX) is oversold because shares have fallen 26% from the high while the business metrics improved; the leadership transition and positioning ahead of results are the best-supported explanations, labelled as inference because no negative company disclosure was found. Filspari sales grew 96%, cash is USD 489.2 million, and the patent runway extends to 2037. The next dated catalysts are the ASN Kidney Week presentations from October 21 to 25 and estimated third quarter results on October 29, 2026. RSI does not imply a rebound.